Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Clin Exp Med ; 28(11): 1451-1457, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31596555

ABSTRACT

BACKGROUND: Assessment of thromboembolic risk is crucial in choosing appropriate treatment in atrial fibrillation (AF). Current guidelines recommend basing the decision on the CHA2DS2-VASc score. However, the score is based only on clinical parameters and therefore its relationship with laboratory-assessed coagulation status might not always be objective. OBJECTIVES: The aim of this study was to assess if the CHA2DS2-VASc score is associated with blood parameters in AF patients. MATERIAL AND METHODS: Patients with continuous AF prequalified for catheter ablation were enrolled into the study and had CHA2DS2-VASc calculated and blood taken for coagulation parameters. RESULTS: The study population comprised of 266 patients (65.0% males; age 57.6 ±10.1 years). Patients were divided into those with CHA2DS2-VASc score 0, and those with ≥1 points, respectively requiring and not requiring anticoagulation treatment. The group with CHA2DS2-VASc = 0 (12% of patients) compared to those with CHA2DS2-VASc ≥ 1 had a significantly lower fibrinogen concentration (285.6 ±82.0 vs 322.6 ±76.4 mg/dL; p = 0.02). Partial thromboplastin time was not significantly different between groups (p > 0.05). Differences were noticed in parameters concerning red blood cells. Lower risk patients had a lower red blood cell count (4.9 ±0.4 vs 5.1 ±6.0 106/µL); p = 0.03), higher hemoglobin concentration (14.9 ±1.0 vs 14.3 ±1.4 g/dL; p = 0.04), and higher hematocrit (43.5 ±2.6 vs 41.7 ±4.7%; p = 0.001). It was observed that along with the increase in CHA2DS2-VASc score mean fibrinogen concentration increased (p-value for trend = 0.04). CONCLUSIONS: In summary, a higher CHA2DS2-VASc score is independently associated with an increase in fibrinogen concentration. Further research is needed to assess the value of fibrinogen in thromboembolic risk assessment.


Subject(s)
Anticoagulants/administration & dosage , Atrial Fibrillation/therapy , Stroke/etiology , Thromboembolism/prevention & control , Aged , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Atrial Fibrillation/drug therapy , Atrial Fibrillation/epidemiology , Atrial Fibrillation/surgery , Catheter Ablation , Female , Fibrinogen , Humans , Male , Middle Aged , Predictive Value of Tests , Risk Assessment/methods , Risk Factors , Stroke/diagnosis , Stroke/mortality , Stroke/prevention & control , Survival Analysis , Thromboembolism/diagnosis , Thromboembolism/etiology , Time Factors , Treatment Outcome
2.
SAGE Open Med Case Rep ; 7: 2050313X19840520, 2019.
Article in English | MEDLINE | ID: mdl-31057796

ABSTRACT

The objective of this case report is to present how the chronic condition significantly complicates life-saving procedures and influences further treatment decisions. A 64-year-old man suffering from arterial hypertension and immune thrombocytopenic purpura presented to the Emergency Department with anterior ST-elevation myocardial infarction. An immediate coronary angiography was performed where critical stenosis of the proximal left anterior descending was found. It was followed by primary percutaneous intervention with bare metal stent. In first laboratory results, extremely low platelet count was found (13 × 109/L). Consulting haematologist advised the use of single antiplatelet therapy and from the second day of hospitalisation only clopidogrel was prescribed. On the sixth day of hospital stay, patient presented acute chest pain with ST elevation in anterior leads. Emergency coronary angiography confirmed acute stent thrombosis and aspiration thrombectomy was performed. It was therefore agreed to continue dual antiplatelet therapy for 4 weeks. As there are no clinical trials where patients with low platelet count are included, all therapeutic decisions must be made based on clinician's experience and experts' consensus. Both the risk of haemorrhagic complications and increased risk of thrombosis must be taken into consideration when deciding on patient's treatment.

3.
SAGE Open Med Case Rep ; 7: 2050313X19838745, 2019.
Article in English | MEDLINE | ID: mdl-30923615

ABSTRACT

Perforations of saphenous venous grafts during coronary angioplasty are rare and potentially lethal. The objective of this clinical case report is to highlight this unusual complication and necessary treatment. A 76-year-old woman, 3 months after coronary artery bypass grafting (left internal mammary artery to left anterior descendant artery, saphenous vein graft to obtuse marginal, saphenous vein graft to right coronary artery), demonstrated typical signs of acute coronary syndrome. Coronary angiogram revealed, inter alia, two critical lesions in saphenous vein graft to right coronary artery. Percutaneous coronary intervention was performed with placement of two drug-eluting stents, complicated by a vessel rupture and heavy extravasation of contrast. A polyurethane-covered stent was then deployed and successfully sealed the vascular wall. In a computed tomography of the chest, a mediastinal haematoma near the heart base and right heart margin was found. Subsequently, this intrathoracic bleeding caused external impression on saphenous vein graft to right coronary artery, leading to near occlusion of the vessel with recurrence of chest pain and ST-segment elevation in inferior wall electrocardiogram leads. Immediate coronary angiography and drug-eluting stent implantation was performed. During, further, in-hospital follow-up, patient was free of chest pain; computed tomography scan performed after 10 days revealed regression of haematoma. Clinicians must remain alert to the potential of life-threatening complications associated with saphenous venous graft angioplasty, as their recognition is critical to institution of prompt, appropriate therapy.

4.
J Vet Res ; 62(3): 365-369, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30584618

ABSTRACT

INTRODUCTION: Ventricular rhythm disturbances are a common pathology in human and veterinary medicine. In humans, the algorithmic approach is used to differentiate wide QRS complex tachycardia. The most commonly used are the aVR and Brugada algorithms as well as the ventricular tachycardia (VT) score developed by Jastrzebski and coworkers. In veterinary medicine, no such algorithms are available and the only parameter used to describe VT abnormalities is the duration of the QRS complexes. The aim of this analysis was determining whether human medicine algorithms for VT are applicable in veterinary medicine to differentiate wide QRS complex tachycardia in dogs. MATERIAL AND METHODS: A retrospective analysis was performed on 11 dogs of both sexes and various breeds and age diagnosed with VT. The diagnosis was based on ambulatory ECG, further established based on the reaction to lidocaine or adenosine or an invasive electrophysiological study. RESULTS: Of the 11 tracings passed through the aVR algorithm, 10 met the VT criteria. The most common criterion was the Vi/Vt ratio (8 out of 11 tracings). Based on the VT score, seven out of eight dogs had a high probability of VT. CONCLUSION: Retrospective analysis of ECGs by aVR and VT score indicates that the applied algorithms may be useful in differentiating wide QRS complex tachycardia as a quick, easy, and non-invasive alternative to cardiac electrophysiology.

5.
J Electrocardiol ; 51(6): 1141-1144, 2018.
Article in English | MEDLINE | ID: mdl-30497746

ABSTRACT

Atrial fibrillation (AF) coexists frequently with heart failure (HF). Permanent His-bundle pacing (pHBP) seems to be an optimal approach to the management of patients with HF and concomitant AF, which are the indication for single chamber ICD implantation. This management allows to up-titrate the beta-blocker dose in order to prevent tachyarrhythmia with no risk of bradyarrhythmia or triggering deleterious right ventricular pacing. We present a case of 69-years-old male with AF, worsening HF and high burden of RV pacing. The upgrade from single chamber ICD to dual chamber ICD with pHBP alleviated the symptoms and contributed to substantial echocardiographic improvement.


Subject(s)
Atrial Fibrillation/therapy , Defibrillators, Implantable , Heart Failure/therapy , Adrenergic beta-Antagonists/therapeutic use , Atrial Fibrillation/complications , Bundle of His , Cardiac Pacing, Artificial , Combined Modality Therapy , Electrocardiography , Heart Failure/complications , Heart Failure/drug therapy , Heart Failure/physiopathology , Humans , Male , Middle Aged , Radiography, Thoracic , Stroke Volume , Ventricular Dysfunction, Left
SELECTION OF CITATIONS
SEARCH DETAIL
...